Xiao Yan Chen

Australian Postal Corp. provides postal and courier services. It also sells mail related products and offers financial services such as bill payment and money transfer. The company was founded on April 25, 1809 and is headquartered in Melbourne, Australia.

Part of GF Securities Co., Ltd., GF Capital (Hong Kong) Ltd. provides corporate finance and related advisory services. The company is based in Hong Kong, Hong Kong.

Harvest Global Investments Ltd. (HGI) is the wholly-owned, Hong Kong-based investment management subsidiary of Harvest Fund Management Co., Ltd. (HFM), an asset management company headquartered in China. Founded in 2008, HGI provides discretionary portfolio management services to their clients, sometimes with the assistance of HFM, serving as the investment adviser to pooled investment vehicles sponsored by other financial firms. They also provide investment advisory services on behalf of sophisticated institutional investors to separately managed accounts.

PegBio Co., Ltd. is a biotechnology company, which engages in the research, development and production of innovative drugs in the field of chronic disease treatment. It focuses in manufacturing polyethylene glycol (PEG) and development of PEGylation technology to PEGylated drugs. The company was founded by Min Xu on May 13, 2008 and is headquartered in Suzhou, China.

Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China.

Legend Star is an investment arm of Legend Holdings Corp. founded in 2008. The firm is headquartered in Beijing, China.

Suzhou Linhwa Medical Devices Co., Ltd. engages in the research, development, production, and sale of clinical vascular drug delivery tools. It offers infusion ports, medical dressings, syringes, needles, and other medical consumables. The company was founded by Lin Yuan Wu on June 28, 1996 and is headquartered in Suzhou, China.

Kontour (Xi'an) Medical Technology Co., Ltd. engages in the research and development, production, and sales service of three types of implanted medical devices. Its products include neurosurgery products, cardiothoracic surgery products, neurospine products, and oral implant system. Its products are used in neurosurgery, skull repair, and cardiothoracic surgery. The company was founded by Li Ren Hu, Li Gong Hu and Di Yuan Huang on March 14, 2005 and is headquartered in Xi'an, China.

Suzhou Kintor Pharmaceuticals, Inc. engages in the technology research and development, technical services, transfer, and advice of drugs and reagents. The company was founded by Youzhi Tong on March 24, 2009 and is headquartered in Suzhou, China.

Jiangsu Yitong Biotechnology Co., Ltd. engages in the development and sale of biotechnology and product. The company was founded on April 20, 2006 and is headquartered in Nanjing, China.

Hunan Yihong Health Technology Co., Ltd. provides health technology solutions. The company is based in Changsha, China. The Chinese company was founded in 2014. The CEO is Shuang Hu.

Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017.

Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China.

Ningbo Taikang Pharmaceutical Technology Co. Ltd. is a private company that develops pharmaceutical technology. The company is based in Ningbo, China.

Shanghai Ennovabio Pharmaceuticals Co. Ltd. is a private company that manufactures pharmaceutical products. The company is based in Shanghai, China.

Suzhou Novartis Pharma Technology Co., Ltd. engages in the production of patented active pharmaceutical ingredients. Its business activities include research and development of patented raw materials, production of dangerous chemicals, and export of products. The company was founded on February 16, 2006 and is headquartered in Changshu, China.